Literature DB >> 8924196

The psychopharmacology of hallucinogens.

H D Abraham1, A M Aldridge, P Gogia.   

Abstract

Hallucinogenic drugs have been inhaled, ingested, worshipped, and reviled since prehistory. With the purification and synthesis of bontanical preparations and the ensuing discovery of chemically unique agents, hope was raised regarding their therapeutic potential, but this hope has been clouded by an epidemic of abuse and an inventory of adverse effects. This review examines aspects of that controversy, including the history of hallucinogens, epidemiology of current hallucinogen abuse, the association of LSD use with prolonged psychoses and hallucinogen persisting perception disorder, and the efforts to demonstrate the drug's therapeutic efficacy. Human subject ramifications in hallucinogen experimentation are discussed. Future lines of research are suggested in human, animal, and tissue culture paradigms.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8924196     DOI: 10.1016/0893-133X(95)00136-2

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  20 in total

Review 1.  Psychedelic medicine: a re-emerging therapeutic paradigm.

Authors:  Kenneth W Tupper; Evan Wood; Richard Yensen; Matthew W Johnson
Journal:  CMAJ       Date:  2015-09-08       Impact factor: 8.262

Review 2.  The behavioral pharmacology of hallucinogens.

Authors:  William E Fantegrossi; Kevin S Murnane; Chad J Reissig
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

Review 3.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

4.  Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.

Authors:  Roland R Griffiths; Matthew W Johnson; William A Richards; Brian D Richards; Una McCann; Robert Jesse
Journal:  Psychopharmacology (Berl)       Date:  2011-06-15       Impact factor: 4.530

5.  Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.

Authors:  R R Griffiths; W A Richards; U McCann; R Jesse
Journal:  Psychopharmacology (Berl)       Date:  2006-07-07       Impact factor: 4.530

6.  New Onset LSD Flashback Syndrome Triggered by the Initiation of SSRIs.

Authors:  Sarah Goldman; David Galarneau; Richard Friedman
Journal:  Ochsner J       Date:  2007

Review 7.  Indolealkylamines: biotransformations and potential drug-drug interactions.

Authors:  Ai-Ming Yu
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

8.  Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.

Authors:  Rr Griffiths; Wa Richards; Mw Johnson; Ud McCann; R Jesse
Journal:  J Psychopharmacol       Date:  2008-07-01       Impact factor: 4.153

9.  Hallucinogen-persisting perception disorder.

Authors:  Leo Hermle; Melanie Simon; Martin Ruchsow; Martin Geppert
Journal:  Ther Adv Psychopharmacol       Date:  2012-10

10.  5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex.

Authors:  V A Vaidya; G J Marek; G K Aghajanian; R S Duman
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.